Matinas Biopharma (MTNB) vs Oragenics (OGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Matinas Biopharma is the larger company by market cap ($890,711 vs $708,377), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MTNB | OGEN |
|---|---|---|
| Share price | $0.7999 | $0.157 |
| Market cap | $890.71K | $708.38K |
| 1-day change | -1.26% | -8.72% |
| EPS (TTM) | $-17.55 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-10.35M | $-9.84M |
| 52-week high | $14.63 | $1.11 |
| 52-week low | $0.75 | $0.13 |
| Distance from 52-week high | -94.53% | -85.86% |
| Average volume | 80.86K | 849.30K |
| Shares outstanding | 1.11M | 4.51M |
| Employees | 2 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Matinas Biopharma
MTNB stock →Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Oragenics
OGEN stock →Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
MTNB vs OGEN FAQ
Which is bigger, Matinas Biopharma or Oragenics?
Matinas Biopharma (MTNB) is larger, with a market capitalization of $890.71K compared with $708.38K for Oragenics (OGEN).
Are Matinas Biopharma and Oragenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.